文献速递消化系统肿瘤支持与姑息治疗

PD-1抗体相关的炎症性胃肠道疾病

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies.
PubMed 文献 · Ann Oncol · 2017-01-01

该回顾性研究通过药物警戒注册系统纳入2013至2016年间疑似抗PD-1相关胃肠道免疫不良事件(GI-irAE)的成人癌症患者,由多学科委员会审核确认。研究提示GI-irAE在抗PD-1治疗中与抗CTLA-4不同且更少见。

要点

  • 抗PD-1治疗下GI-irAE发生率估计为1.5%,中位发生时间4.2个月。
  • 确诊GI-irAE患者中腹泻80%、腹痛65%、恶心呕吐55%。
  • 急性结肠炎激素应答率87.5%,显微镜结肠炎57%,上消化道炎症75%。

核心结论

  • 本研究提示GI-irAE在抗PD-1治疗中与抗CTLA-4不同且更少见。

研究设计与样本

  • 回顾性研究,纳入2013至2016年间通过药物警戒注册系统招募的连续成人癌症患者,这些患者疑似因抗PD-1抗体出现GI-irAE。
  • 患者数据由包括胃肠病学家、肿瘤学家和病理学家的多学科委员会审核。
  • 定量变量以中位数(范围)描述,定性变量以频率(百分比)描述。

主要发现

  • GI-irAE发生于抗PD-1启动后4.2个月(0.2; 22.1)。
  • 抗PD-1治疗下GI-irAE发生率估计为1.5%。
  • 确诊患者中主要症状为腹泻(n=16, 80%)、腹痛(n=13, 65%)、恶心呕吐(n=11, 55%)、肠梗阻(n=1, 5%)、便血(n=2, 10%),无患者行结肠切除术。
  • GI-irAE分为四类:急性结肠炎(n=8, 40%)、显微镜结肠炎(n=7, 35%)、上消化道炎症(n=4, 20%)、假性梗阻(n=1, 5%)。

关键数值与推荐

  • 激素应答率:急性结肠炎87.5%(7/8),显微镜结肠炎57%(4/7),上消化道炎症75%(3/4)。
  • 中位缓解时间:急性结肠炎36天(6-172),显微镜结肠炎98天(42-226)。

临床怎么用

  • 原文未提及临床实践指导。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune check-point blockade agents have shown clinical activity in cancer patients but are associated with immune-related adverse events that could limit their development. The aim of this study was to describe the gastrointestinal immune-related adverse events (GI-irAE) in patients with cancer treated with anti-PD-1. METHODS: this is a retrospective study of consecutive adult patients who had a suspected GI-irAE due to anti-PD-1 antibodies between 2013 and 2016. Patients were recruited through a pharmacovigilance registry. Patients' data were reviewed by a multidisciplinary committee that included gastroenterologists, oncologists and a pathologist. Quantitative variables are described by median (range), qualitative variable by frequency (percentage). RESULTS: Forty-four patients were addressed to a Gastroenterology unit for a suspected GI-IrAE. Twenty patients had a confirmed GI-irAE related to anti-PD-1, which occurred 4.2 months (0.2; 22.1) after the initiation of anti-PD-1. GI-IrAE incidence rate under anti-PD-1 treatment was estimated to be 1.5%. Among patients with GI-IrAE, main symptoms were diarrhoea (n = 16, 80%), abdominal pain (n = 13, 65%), nausea and vomiting (n = 11, 55%), intestinal obstruction (n = 1, 5%), and haematochezia (n = 2, 10%). No patient had colectomy. Four distinct categories of GI-irAE were observed: acute colitis (n = 8, 40%), microscopic colitis (n = 7, 35%), upper gastrointestinal tract inflammation (n = 4, 20%) and pseudo-obstruction (n = 1, 5%). Response rates to corticosteroids were 87.5% (7/8) in acute colitis, 57% (4/7) in microscopic colitis and 75% (3/4) in upper gastrointestinal tract inflammation. Median time to resolution was 36 days (6-172) in acute colitis, and 98 days (42-226) in microscopic colitis. CONCLUSION: This study suggests that GI-irAE are different and less frequent with anti PD-1 than with anti CTLA-4.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Collins M, Michot JM, Danlos FX, et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol. 2017. PMID: 29045560. doi:10.1093/annonc/mdx403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。